Unique ID issued by UMIN | UMIN000009994 |
---|---|
Receipt number | R000011702 |
Scientific Title | Clinical trial evaluating dendritic cell vaccination as an adjuvant immunotherapy in patients with pancreatic cancer |
Date of disclosure of the study information | 2013/02/07 |
Last modified on | 2013/02/07 18:46:38 |
Clinical trial evaluating dendritic cell vaccination as an adjuvant immunotherapy in patients with pancreatic cancer
Clinical trial of dendritic cell vaccination as an adjuvant immunotherapy in patients with pancreatic cancer
Clinical trial evaluating dendritic cell vaccination as an adjuvant immunotherapy in patients with pancreatic cancer
Clinical trial of dendritic cell vaccination as an adjuvant immunotherapy in patients with pancreatic cancer
Japan |
Pancreatic cancer
Hepato-biliary-pancreatic surgery |
Malignancy
NO
To evaluate the efficacy of dendritic cell vaccination as an adjuvant immunotherapy combined with chemotherapy for patients with resected pancreatic cancer
Efficacy
Tumor-specific immune responses
Relapse free survival
Overall survival
Tumor marker
Quality of life
Interventional
Single arm
Non-randomized
Open -no one is blinded
Active
1
Treatment
Vaccine |
Resected tumor-pulsed dendritic cells or MUC-1 peptide-pulsed dendritic cells
20 | years-old | <= |
Not applicable |
Male and Female
(1)Patients with histologically diagnosed and informed pancreatic cancer.
(2)Patients with 20 years of age or older.
(3)Patients with resectable or resected pancreatic cancer.
(4)Tumors expressed MHC class1 or MUC-1.
(5)Patients with PS0-2.
(6)Patients can visit seta clinic.
(7)Patients with expected survival of 3 months or longer.
(8)Patients with no bone-marrow, liver or renal dysfunction.
(9)Patients can be conducted apheresis.
(10)Written informed consent from patients.
(1)Patients with sighs or history of interstitial pneumonia.
(2)Patients with autoimmune diseases.
(3)Patients with uncontrolable infectious diseases.
(4)Patients with history of severe heart diseases.
(5)Patients with history of severe drug allergy.
(6)Patients received continuous administration of steroids.
(7)Patients with pregnant or probability of pregnancy or breast-feeding.
(8)Patients with HIV or HTLV-1 infection in 6 months.
(9)Patients considered inadequate for this trial by physician-in-charge.
20
1st name | |
Middle name | |
Last name | Koichi Taniguchi |
Yokohama City University
Department of Gastroenterological Surgery
3-9 Fukuura, Kanazawa-ku, Yokohama city
1st name | |
Middle name | |
Last name |
Yokohama City University
Gastroenterological Surgery
t1006koichi@yahoo.co.jp
Yokohama City University, Gastroenterological Surgery
None
Other
Seta clinic group
NO
2013 | Year | 02 | Month | 07 | Day |
Unpublished
Open public recruiting
2012 | Year | 10 | Month | 01 | Day |
2012 | Year | 10 | Month | 01 | Day |
2013 | Year | 02 | Month | 07 | Day |
2013 | Year | 02 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011702
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |